Capital Research Global Investors Portfolio holdings
Capital Research Global Investors (CRGI), a division of Capital Group established in 1931 and headquartered in Los Angeles, California, is a powerhouse in active investment management, overseeing hundreds of billions in assets with a focus on global equity portfolios. Known for its long-term, research-intensive approach, CRGI employs a unique multiple-portfolio-manager system to diversify risk and enhance returns, serving institutional clients, financial advisors, and individual investors through vehicles like the American Funds mutual fund family. The firm’s investment philosophy emphasizes fundamental analysis and a deep understanding of companies worldwide, aiming to identify growth opportunities over extended horizons. As part of Capital Group’s broader mission, CRGI has built a reputation for delivering consistent, value-driven results in the global investment landscape.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
MON
Monsanto Co
MON
|
+$1.07B |
| 2 |
Cisco
CSCO
|
+$871M |
| 3 |
Alibaba
BABA
|
+$729M |
| 4 |
Booking.com
BKNG
|
+$567M |
| 5 |
Ventas
VTR
|
+$557M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$1.52B |
| 2 |
Yum! Brands
YUM
|
+$923M |
| 3 |
Biogen
BIIB
|
+$904M |
| 4 |
Oracle
ORCL
|
+$823M |
| 5 |
BHI
Baker Hughes
BHI
|
+$597M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 21.41% |
| 2 | Technology | 12.87% |
| 3 | Industrials | 11.05% |
| 4 | Communication Services | 10.38% |
| 5 | Consumer Staples | 8.5% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Stryker
SYK
$133B
| $2.19B | 0.76% |
27,084,821
+1,334,379
| +5% | +$110M |
|
27
Lockheed Martin
LMT
$140B
| $2.17B | 0.75% |
11,884,360
-1,100,000
| -8% | -$187M |
|
|
PX
28
DELISTED
Praxair Inc
PX
| $2.16B | 0.75% |
16,774,012
+253,000
| +2% | +$33.2M |
|
29
Exelon
EXC
$46.6B
| $2.14B | 0.74% |
88,119,710
-11,027,417
| -11% | -$258M |
|
30
SLB Ltd
SLB
$78.1B
| $2.06B | 0.71% |
20,302,399
-673,000
| -3% | -$73.4M |
|
31
Microsoft
MSFT
$3.66T
| $2.05B | 0.71% |
44,296,448
-909,000
| -2% | -$40.5M |
|
32
Nike
NKE
$60.1B
| $1.95B | 0.67% |
43,699,048
-411,520
| -0.9% | -$16.3M |
|
33
Thermo Fisher Scientific
TMO
$223B
| $1.93B | 0.67% |
15,896,900
-18,400
| -0.1% | -$2.24M |
|
|
PCP
34
DELISTED
PRECISION CASTPARTS CORP
PCP
| $1.91B | 0.66% |
8,055,017
+866,399
| +12% | +$210M |
|
35
GE Aerospace
GE
$379B
| $1.9B | 0.66% |
15,466,034
-333,338
| -2% | -$41.5M |
|
|
STJ
36
DELISTED
St Jude Medical
STJ
| $1.82B | 0.63% |
30,302,171
+393,000
| +1% | +$25.7M |
|
|
37
Biogen
BIIB
$30.9B
| $1.81B | 0.62% |
5,456,600
-2,741,950
| -33% | -$904M |
|
38
Dominion Energy
D
$59.8B
| $1.79B | 0.62% |
25,913,226
+991,000
| +4% | +$68.4M |
|
39
American International
AIG
$39.8B
| $1.77B | 0.61% |
32,835,275
+4,123,700
| +14% | +$225M |
|
|
BRCM
40
DELISTED
BROADCOM CORP CL-A
BRCM
| $1.74B | 0.6% |
43,041,690
-1,518,950
| -3% | -$59M |
|
|
TWX
41
DELISTED
Time Warner Inc
TWX
| $1.71B | 0.59% |
22,772,836
-190,000
| -0.8% | -$14.7M |
|
|
BHI
42
DELISTED
Baker Hughes
BHI
| $1.7B | 0.59% |
26,152,828
-8,561,965
| -25% | -$597M |
|
43
Coca-Cola
KO
$373B
| $1.69B | 0.59% |
39,617,600
-3,606,800
| -8% | -$149M |
|
44
Teva Pharmaceuticals
TEVA
$42.8B
| $1.68B | 0.58% |
31,192,152
-1,703,000
| -5% | -$90.2M |
|
45
Canadian Natural Resources
CNQ
$98.1B
| $1.63B | 0.56% |
86,869,727
+24,049,743
| +38% | +$497M |
|
46
Kinder Morgan
KMI
$70.7B
| $1.6B | 0.55% |
41,758,313
+5,749,000
| +16% | +$218M |
|
47
Intuit
INTU
$91.6B
| $1.59B | 0.55% |
18,094,600
| – | – |
|
48
DuPont de Nemours
DD
$19.5B
| $1.58B | 0.55% |
11,919,310
| – | – |
|
49
Illumina
ILMN
$29.1B
| $1.52B | 0.53% |
9,541,471
-51,400
| -0.5% | -$8.59M |
|
50
AT&T
T
$166B
| $1.51B | 0.52% |
56,762,276
| – | – |
|
Similar funds
Capital Research Global Investors's Q3 2014 Portfolio in Review
As of Q3 2014, Capital Research Global Investors held 464 positions worth $289B, up 1% from $286B the previous quarter. Its ten largest holdings account for 27% of the portfolio.
Capital Research Global Investors's Q3 2014 filing shows 29 new, 121 increased, 131 reduced and 23 closed positions. Its largest new stake was Alibaba: 8,115,335 shares worth $721M. The largest sale was Gilead Sciences, an estimated $1.52B.
By sector, the portfolio is most concentrated in Healthcare at 21% of assets, up from 20% a quarter earlier, followed by Technology and Industrials.
- Capital Research Global Investors's largest Q3 2014 buy was Alibaba: 8,115,335 shares worth $721M.
- Capital Research Global Investors added most to Monsanto Co in Q3 2014, an estimated $1.07B increase.
- Capital Research Global Investors's biggest Q3 2014 reduction was Gilead Sciences, cutting an estimated $1.52B.
- Capital Research Global Investors fully exited OPENTABLE,INC COMMON STOCK in Q3 2014, selling an estimated $155M.
- Capital Research Global Investors's ten largest holdings make up 27% of its $289B portfolio in Q3 2014.
- Capital Research Global Investors opened 29 new positions and closed 23 in Q3 2014.
- Capital Research Global Investors's portfolio value rose 1% quarter-over-quarter to $289B.
Based on Capital Research Global Investors's 13F filing for Q3 2014, filed 14 Nov 2014.